{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:49:23Z","timestamp":1792676963307,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.phrs.2024.107401","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T04:30:48Z","timestamp":1725683448000},"page":"107401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"208","author":[{"given":"Gisella","family":"Figlioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Piovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Peppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Repici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.phrs.2024.107401_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2024.107401_bib2","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/cvr\/cvab249","article-title":"Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?","volume":"117","author":"Lehmann","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2024.107401_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"9548","key":"10.1016\/j.phrs.2024.107401_bib4","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2024.107401_bib5","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab065","article-title":"The role of incretins on insulin function and glucose homeostasis","volume":"162","author":"Holst","year":"2021","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.phrs.2024.107401_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2024.107401_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"18","key":"10.1016\/j.phrs.2024.107401_bib8","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.phrs.2024.107401_bib9","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","volume":"36","author":"Butler","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.phrs.2024.107401_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14740338.2015.987122","article-title":"Potential side effects to GLP-1 agonists: understanding their safety and tolerability","volume":"14","author":"Consoli","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2024.107401_bib11","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk?","volume":"36 Suppl 2","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.phrs.2024.107401_bib12","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2024.107401_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2024.107401_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","article-title":"GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7","volume":"21","author":"Koehler","year":"2015","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.phrs.2024.107401_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.phrs.2024.107401_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1534365","article-title":"Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"J. Diabetes Res."},{"issue":"2","key":"10.1016\/j.phrs.2024.107401_bib17","first-page":"206","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol. (Torino)"},{"issue":"3","key":"10.1016\/j.phrs.2024.107401_bib18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2024.107401_bib19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/MPA.0000000000002197","article-title":"Glucagon-like peptide 1-based therapies and risk of pancreatic cancer in patients with diabetes and obesity","volume":"51","author":"Krishnan","year":"2022","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.phrs.2024.107401_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2024.107401_bib21","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2024.107401_bib22","unstructured":"Higgins J.P. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated 2022). Cochrane, 2022. Available from \u3008www.training.cochrane.org\/handbook\u3009."},{"issue":"4","key":"10.1016\/j.phrs.2024.107401_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.phrs.2024.107401_bib24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.phrs.2024.107401_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"7650","key":"10.1016\/j.phrs.2024.107401_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2024.107401_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Schunemann","year":"2022","journal-title":"J. Clin. Epidemiol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107401_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat. Med"},{"issue":"7414","key":"10.1016\/j.phrs.2024.107401_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"DG. Measuring inconsistency in meta-analyses","volume":"327","author":"Thompson","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.phrs.2024.107401_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"7109","key":"10.1016\/j.phrs.2024.107401_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"C. Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2024.107401_bib32","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"10296","key":"10.1016\/j.phrs.2024.107401_bib33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2024.107401_bib34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int J. Eat. Disord."},{"key":"10.1016\/j.phrs.2024.107401_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/CLEP.S456170","article-title":"Semaglutide (Ozempic((R))) use in denmark 2018 through 2023-user trends and off-label prescribing for weight loss","volume":"16","author":"Mailhac","year":"2024","journal-title":"Clin. Epidemiol."},{"issue":"20","key":"10.1016\/j.phrs.2024.107401_bib36","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMp2400978","article-title":"Fair allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists","volume":"390","author":"Emanuel","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107401_bib37","doi-asserted-by":"crossref","first-page":"q28","DOI":"10.1136\/bmj.q28","article-title":"GLP-1 agonist shortage will last until end of 2024, government warns","volume":"384","author":"Mahase","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.phrs.2024.107401_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.phrs.2024.107401_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"issue":"10193","key":"10.1016\/j.phrs.2024.107401_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2024.107401_bib41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2024.107401_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T19:12:27Z","timestamp":1726773147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824003463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":42,"alternative-id":["S1043661824003463"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107401","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107401"}}